Zhengye Biotechnology Holding Limited (ZYBT) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
9.15
—
5yr avg: N/A
P/FCF
22.88
—
5yr avg: N/A
P/B Ratio
0.86
—
5yr avg: N/A
ROE
↓
3.3%
↑-66% vs avg
5yr avg: 9.6%
30Y Low3%·High14%
Debt/EBITDA
↑
2.13
↑+84% vs avg
5yr avg: 1.16
30Y Low0.4·High2.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZYBT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
On a free-cash-flow basis, the stock trades at 22.9x P/FCF.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $45M | — | — | — | — |
| Enterprise Value | $55M | — | — | — | — |
| P/E Ratio → | — | — | — | — | — |
| P/S Ratio | 1.63 | — | — | — | — |
| P/B Ratio | 0.86 | — | — | — | — |
| P/FCF | 22.88 | — | — | — | — |
| P/OCF | 7.40 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZYBT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Zhengye Biotechnology Holding Limited's enterprise value stands at 9.2x EBITDA. The Healthcare sector median is 14.4x, placing the stock at a 36% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | 9.15 | — | — | — | — |
| EV / EBIT | 22.60 | — | — | — | — |
| EV / FCF | — | — | — | — | — |
ZYBT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Zhengye Biotechnology Holding Limited earns an operating margin of 8.8%. Operating margins have compressed from 25.3% to 8.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 3.3% is modest. ROIC of 3.0% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 49.0% | 49.0% | 61.4% | 59.0% | 58.6% |
| Operating Margin | 8.8% | 8.8% | 21.3% | 25.3% | 24.5% |
| Net Profit Margin | 6.1% | 6.1% | 14.9% | 18.0% | 18.2% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | 3.3% | 3.3% | 9.0% | 13.8% | 12.2% |
| ROA | 2.3% | 2.3% | 6.2% | 9.7% | 8.7% |
| ROIC | 3.0% | 3.0% | 8.2% | 13.1% | 11.5% |
| ROCE | 4.7% | 4.7% | 12.5% | 19.2% | 16.4% |
ZYBT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Zhengye Biotechnology Holding Limited carries a Debt/EBITDA ratio of 2.1x, which is manageable (35% below the sector average of 3.3x). Net debt stands at $68M ($86M total debt minus $19M cash). Interest coverage of 4.1x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.26 | 0.18 | 0.09 |
| Debt / EBITDA | 2.13 | 2.13 | 1.30 | 0.77 | 0.44 |
| Net Debt / Equity | — | 0.19 | 0.22 | 0.15 | 0.07 |
| Net Debt / EBITDA | 1.67 | 1.67 | 1.09 | 0.65 | 0.35 |
| Debt / FCF | — | 5.11 | 2.04 | — | 4.38 |
| Interest Coverage | 4.07 | 4.07 | 10.17 | 23.19 | 50.08 |
ZYBT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.31x means Zhengye Biotechnology Holding Limited can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.88x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.41x to 1.31x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 1.31 | 1.31 | 1.37 | 1.41 | 1.31 |
| Quick Ratio | 0.88 | 0.88 | 0.98 | 1.04 | 0.97 |
| Cash Ratio | 0.15 | 0.15 | 0.11 | 0.06 | 0.05 |
| Asset Turnover | — | 0.38 | 0.42 | 0.50 | 0.48 |
| Inventory Turnover | 1.63 | 1.63 | 1.40 | 1.93 | 2.03 |
| Days Sales Outstanding | — | 173.37 | 171.46 | 188.27 | 174.24 |
ZYBT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zhengye Biotechnology Holding Limited returns 5.3% to shareholders annually primarily through dividends. The payout ratio exceeds 100% at 141.7%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | 5.3% | — | — | — | — |
| Payout Ratio | 141.7% | 141.7% | 125.4% | 45.8% | 28.4% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | 4.4% | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — |
| Total Shareholder Yield | 5.3% | — | — | — | — |
| Shares Outstanding | — | $0 | $0 | $0 | $0 |
Peer Comparison
Compare ZYBT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZYBTYou | $45M | — | 9.2 | 22.9 | 49.0% | 8.8% | 3.3% | 3.0% | 2.1 |
 ATXG | $3M | -0.4 | — | 4.6 | 15.2% | -43.5% | -21.3% | -2.9% | — |
 CLPS | $25M | -3.5 | — | — | 20.9% | -4.0% | -11.6% | -7.9% | — |
 TAOP | $1M | -0.2 | — | — | 10.9% | -29.0% | -56.8% | -27.1% | — |
 CNET | $2M | -0.4 | — | — | 2.9% | -24.3% | -75.4% | -64.7% | — |
 AGRI | $311837 | -0.0 | — | — | -31.3% | -15322.6% | -221.8% | -98.0% | — |
 SEED | $9M | -1.1 | — | — | 7.0% | -58.9% | — | — | — |
 HNVR | $167M | 23.3 | 9.4 | 12.8 | 43.9% | 6.9% | 3.8% | 2.2% | 13.7 |
 BTBT | $589M | 9.2 | 8.5 | — | 61.9% | 16.8% | 9.2% | 6.5% | 0.2 |
 PLAG | $14M | -1.9 | — | 15.2 | 11.3% | -99.0% | -47.1% | -27.3% | — |
 CTGO | $371M | -7.1 | — | 531.4 | — | — | -2988.3% | -35.6% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See ZYBT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZYBT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZYBT vs ATXG
Side-by-side business, growth, and profitability comparison vs Addentax Group Corp..
Start ComparisonZYBT — Frequently Asked Questions
Quick answers to the most common questions about buying ZYBT stock.
What is Zhengye Biotechnology Holding Limited's EV/EBITDA?
Zhengye Biotechnology Holding Limited's current EV/EBITDA is 9.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Zhengye Biotechnology Holding Limited's ROE?
Zhengye Biotechnology Holding Limited's return on equity (ROE) is 3.3%. The historical average is 9.6%.
Is ZYBT stock overvalued?
Based on historical data, Zhengye Biotechnology Holding Limited is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
What is Zhengye Biotechnology Holding Limited's dividend yield?
Zhengye Biotechnology Holding Limited's current dividend yield is 5.28% with a payout ratio of 141.7%.
What are Zhengye Biotechnology Holding Limited's profit margins?
Zhengye Biotechnology Holding Limited has 49.0% gross margin and 8.8% operating margin.
How much debt does Zhengye Biotechnology Holding Limited have?
Zhengye Biotechnology Holding Limited's Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.